Containing Polysaccharides (e.g., Sugars) Patents (Class 424/493)
-
Publication number: 20140186426Abstract: This invention relates, e.g., to a molecular delivery system comprising A. a substrate having a nanostructured surface region which comprises a plurality of nanostructures and, covalently attached to the substrate, multiple copies of a first member of a binding pair; and B. at least one vector nanoparticle which comprises, encapsulated therein, a molecule of interest, and on its surface, multiple copies of second member of the binding pair. Methods of using the molecular delivery system to deliver a molecule of interest to a cell are also described.Type: ApplicationFiled: July 23, 2012Publication date: July 3, 2014Applicant: The Regents of the University of CaliforniaInventors: Hsian-Rong Tseng, Hao Wang, Kuan-Ju Chen
-
Patent number: 8765184Abstract: The present invention relates to a method for preparing solid pharmaceutical compositions comprising fine particles of at least one active substance, dispersed on and (or) within a divided solid. This method is characterized in that a solution is formed which comprises at least one active substance in a fluid at supercritical pressure, said solution then being expanded in a chamber under temperature and pressure conditions for which a part of said fluid is in the liquid state at the time of the expansion, said fluid thus expanded being brought into contact with a divided solid in said chamber.Type: GrantFiled: March 30, 2010Date of Patent: July 1, 2014Assignee: StanipharmInventors: Frantz Deschamps, Jennifer Jung, Fabrice Leboeuf
-
Patent number: 8765186Abstract: The present invention relates to a process for the manufacture of an emulsion or dispersion containing one or more carotenoids, in a preferred embodiment it relates to the manufacture of a powder containing one or more carotenoids, furthermore to the powder obtainable by said process and a food composition, especially a beverage, containing said powder.Type: GrantFiled: March 4, 2008Date of Patent: July 1, 2014Assignee: DSM IP Assets B.V.Inventors: Christian Schäfer, David Schaffner
-
Patent number: 8765187Abstract: Disclosed is an aqueous composition containing (a) an ethyl acrylate/methyl methacrylate copolymer or a plasticized vinyl accetate polymer, (b) an ethyl cellulose, (c) a water soluble additive for pharmaceutical products, (d) titanium oxide and (c) water. The solid content mass ratio among the components (a), (b), (c) and (d), namely a:b:c:d is 100:(5-50):(1-50):(0.5-10), and the solid content concentration in the aqueous composition is 0.5-40% by mass.Type: GrantFiled: July 16, 2008Date of Patent: July 1, 2014Assignee: Asahi Kasei Chemicals CorporationInventors: Yoshihito Yaginuma, Naoya Yoshida
-
Publication number: 20140178310Abstract: Iron oxide complexes, pharmacological compositions and unit dosage thereof, and methods for their administration, of the type employing an iron oxide complex with a polyol, are disclosed. The pharmacological compositions employ a polysaccharide iron oxide complex, wherein the polysaccharide is a modified polyol such as a carboxyalkylated reduced dextran. The complex is stable to terminal sterilization by autoclaving. The compositions are suitable for parenteral administration to a subject for the treatment of iron deficiencies or as MRI contrast agent. The complex is substantially immunosilent, provide minimal anaphylaxis and undergo minimal dissolution in vivo. The pharmacological compositions of the complex contain minimal free iron which can be quantified by a variety of methods.Type: ApplicationFiled: July 9, 2013Publication date: June 26, 2014Inventors: Ernest V. Groman, Kenneth G. Paul, Timothy B. Frigo, Howard Bengele, Jerome M. Lewis
-
Patent number: 8747903Abstract: The present invention relates to a composition for nucleic acid delivery and a method for preparing the same, more particularly to a composition for nucleic acid delivery having excellent stability in the body environment and excellent intracellular delivery efficiency of nucleic acid, and enabling target directed delivery of nucleic acid, and a method for preparing the same.Type: GrantFiled: March 27, 2012Date of Patent: June 10, 2014Assignee: Postech Academy-Industry FoundationInventors: Sei Kwang Hahn, Min-Young Lee, Kitae Park, Ki Su Kim, Hwiwon Lee
-
Publication number: 20140147508Abstract: The present invention relates to a nano-carrier for an anticancer drug, which comprises: a metal nanoparticle; and a polynucleotide for connecting with an anticancer drug having a pyrimidine group or a purine group, wherein the polynucleotide is connected to a surface of the metal nanoparticle, and the anticancer drug is bound to the polynucleotide through the pyrimidine group or the purine group. In addition, the present invention also provides a complex of an anticancer drug and a nano-carrier, a pharmaceutical composition thereof, a method for manufacturing the complex, and a method for treating a cancer by using the pharmaceutical composition.Type: ApplicationFiled: January 29, 2014Publication date: May 29, 2014Applicant: National Cheng Kung UniversityInventors: Dar-Bin SHIEH, Chen-Sheng YEH, Dong-Hwang CHEN, Ya-Na WU, Ping-Ching WU
-
Publication number: 20140147501Abstract: Controlled release, discrete, solid particles which contain an encapsulated and/or embedded component such as a heat sensitive or readily oxidizable pharmaceutically, biologically, or nutritionally active component are continuously produced without substantial destruction of the matrix material or encapsulant. A release-rate controlling component is incorporated into the matrix to control the rate of release of the encapsulant from the particles. The additional component may be a hydrophobic component or a high water binding capacity component for extending the release time. The plasticizable matrix material, such as starch, is admixed with at least one plasticizer, such as water, and at least one release-rate controlling component under low shear mixing conditions to plasticize the plasticizable material without substantially destroying the at least one plasticizable material and to obtain a substantially homogeneous plasticized mass.Type: ApplicationFiled: January 29, 2014Publication date: May 29, 2014Applicant: GENERAL MILLS, INC.Inventor: Bernhard H. VAN LENGERICH
-
Patent number: 8734849Abstract: The invention relates to an oral, multiparticle pharmaceutical dosage form containing pellets, the size of which ranges from 50 to 2500 ?m and which essentially consist of: a) an inner matrix layer containing an active substance which is a peptide or a protein, including the derivatives or conjugates thereof, and which is embedded in a matrix consisting of a polymer with mucoadhesive effect, and b) an outer film coating essentially consisting of an anionic polymer or copolymer, which can be optionally formulated with pharmaceutically conventional adjuvants, more particularly softening agents.Type: GrantFiled: July 15, 2004Date of Patent: May 27, 2014Assignee: Evonik Roehm GmbHInventors: Rosario Lízio, Hans-Ulrich Petereit, Erna Roth, Inès Andres, Michael Damm
-
Publication number: 20140127308Abstract: A composition comprising microcapsules, the microcapsules containing both live mammalian ovarian granulosa cells and live mammalian ovarian theca cells, is described. In some embodiments, the granulosa cells and the theca cells are contained in separate microcapsules in the composition; in some embodiments, the granulosa cells and the theca cells are contained together in the same microcapsules in the composition The composition is can be used for estrogen, and optionally also progesterone, delivery, and hence is preferably free or essentially free of oocytes. Methods of using the same and pharmaceutical formulations containing the same are also described.Type: ApplicationFiled: February 21, 2012Publication date: May 8, 2014Applicant: Wake Forest University Health SciencesInventors: Emmanuel Opara, James J. Yoo, Justin M. Saul, Sittadjody Sivanandane, Anthony Atala
-
Patent number: 8715739Abstract: Methods for preparing uniformly sized micropanicles, with an optional polymeric coating generally include: 1) providing nanoparticles, preferably having a size of between 1 nm and 100 nm; 2) adding a hydrophobic surface layer to the nanoparticles; 3) making a suspension of the hydrophobic nanoparticles and a polymerization initiator in an hydrophobic solvent; 4) dissolving a monomer in the hydrophobic solvent; 5) making an emulsion by dispersing droplets of the hydrophobic solvent in a continuous aqueous phase with an emulsifier; 6) sizing the first emulsion to provide a second emulsion of the same components in which the droplets are substantially uniform and between 2 and 20 um in size; 7) evaporating at least a substantial portion of the dispersed hydrophobic droplets to assemble nanoparticles to form micropanicles suspended now in the aqueous phase; 8) replacing the first surfactant with a second surfactant, which is preferably a polymerizable surfactant; 9) adding a polymerizable monomer to the aqueous pType: GrantFiled: October 24, 2006Date of Patent: May 6, 2014Assignee: Purdue Research FoundationInventors: Gil U. Lee, Hao Shang, Won-Suk Chang
-
Patent number: 8709489Abstract: The invention provides emulsion compositions that include a hydrophobic compound and an arylboronic acid. An exemplary emulsion comprises a hydrophobic polymer and a halogenated arylboronic acid. Use of an arylboronic acid provides the emulsion with exceptional stability. The stability provides advantages for the formation of articles formed from the emulsion, including microparticles, as well as other implantable or injectable medical articles having polymeric matrices.Type: GrantFiled: September 30, 2010Date of Patent: April 29, 2014Assignee: SurModics, Inc.Inventors: Joram Slager, Aleksey V. Kurdyumov, Dale G. Swan
-
Patent number: 8703203Abstract: The invention relates to an oral dosage form containing deferasirox, binder, disintegrant and optionally wicking agent, wherein the introduction of the dosage form into water leads to a suspension wherein the suspended particles have an average particle size (D50) of 20 ?m to 120 ?m, and also to a method of producing it.Type: GrantFiled: July 7, 2011Date of Patent: April 22, 2014Assignee: ratiopharm GmbHInventors: Jana Paetz, Katrin Rimkus
-
Patent number: 8703202Abstract: Disclosed is a pharmaceutically acceptable oral dosage form comprising fenofibrate, phospholipid, a buffer salt, a water-soluble bulking agent selected from maltodextrin, mannitol, and combinations thereof, a cellulosic additive, beads or crystals of a pharmaceutically acceptable water-soluble excipient support material, a polyvinylpyrrolidone or crospovidone, croscarmellose sodium, granular mannitol, sodium dodecyl sulfate, silicon dioxide, and a stearate, wherein the fenofibrate is in the form of microparticles, and wherein at least a portion of the phospholipid is coated on the surfaces of the fenofibrate microparticles, the phospholipid coated microparticles are embedded in a matrix comprising the water-soluble bulking agent, phospholipid that is not coated on the microparticles, the buffer salt and the cellulosic additive, and the matrix is coated on up to 100% of the surfaces of the beads or crystals of the excipient support material.Type: GrantFiled: July 24, 2006Date of Patent: April 22, 2014Assignee: Jagotec AGInventors: Michael Vachon, Mishra K. Awadhesh, Robert A. Snow, Pol-Henri Guivarc'h
-
Publication number: 20140105994Abstract: The invention relates to a microencapsulated amino acid composition and methods of manufacturing this composition. Amino acids, such as branched-chain amino acids, have low water solubility, poor hydrophilicity, and poor stability. Amino acids are thus difficult to be digested and absorbed. Consequently amino acids can hardly meet human needs of consuming. This microencapsulated amino acid composition that can quickly disperse and dissolve in cold water, resulting clear solution. The method includes (1) adding coating agents, wetting agents, or other excipients to the amino acid mixture, (2) modifying the surface of microencapsulated particles to considerably accelerate the wetting speed. In this composition, the weight ratio of amino acids and excipients is from 100/0.1 to 100/10.0.Type: ApplicationFiled: October 11, 2013Publication date: April 17, 2014Applicant: INNOBIO LIMITEDInventors: Wenzhong WU, Jianbin CHEN, Yuemei ZHANG
-
Publication number: 20140105991Abstract: The present invention provides spherical microcapsules comprising at least one surface coating and a core, wherein the at least one surface coating comprises cross-linked polymers, and wherein the core comprises cross-linked polymers and cells capable of expressing and secreting a GLP-1 peptide, a fragment or variant thereof or a fusion peptide comprising GLP-1 or a fragment or variant thereof. The present applicators is furthermore directed to methods for production of these spherical microcapsules and to the use of these microcapules e.g. in the treatment of type 2 diabetes, weight disorders and diseases or conditions associated thereto, neurodegenerative disorders and diseases or conditions associated thereto, or for the treatment of disorders and diseases or conditions associated to apoptosis.Type: ApplicationFiled: October 16, 2012Publication date: April 17, 2014Applicant: BIOCOMPATIBLES UK LTD.Inventors: Peter GEIGLE, Christine Wallrapp, Eric Thoenes, Frank Thurmer
-
Publication number: 20140105828Abstract: This disclosure relates to nanoparticles carrying nucleic acid cassettes for expressing RNA. In certain embodiments, the disclosure relates to improved methods for targeted delivery and expression of siRNAs in vivo using DNA-based siRNA-expressing nanocassettes and receptor-targeted nanoparticles. In certain embodiments, the disclosure relates to methods of targeted delivery of survivin siRNA expressing nanocassettes which enhance sensitivity of human cancer cells to anticancer agents.Type: ApplicationFiled: October 14, 2013Publication date: April 17, 2014Applicant: Emory UniversityInventor: Lily Yang
-
Patent number: 8697133Abstract: The present invention relates to the provision of micron or sub-micron sized particles formed from one or more water-soluble crystals comprising a surface coating comprising one or more bioactive molecules wherein the particles are prepared such that in use the release of the bioactive molecule(s) is/are delayed and/or continually released over a period of time. Processes for the preparation of said particles, as well as the particles themselves are described, as well as uses of the particles.Type: GrantFiled: December 15, 2008Date of Patent: April 15, 2014Assignee: University of StrathclydeInventors: Barry Douglas Moore, Johann Partridge, Louise Bradley, Jan Vos
-
Publication number: 20140093575Abstract: Systems and methods for coating a particle core with a layer-by-layer film are disclosed.Type: ApplicationFiled: April 23, 2013Publication date: April 3, 2014Applicant: Massachusetts Institute of TechnologyInventor: Massachusetts Institute of Technology
-
Patent number: 8679512Abstract: Topically administering a propellant-free formulation as a spray in the form of aqueous suspension of drug particles, wherein said formulation consists essentially of: micronized particles of beclometasone dipropionate (BDP) suspended in an aqueous phase, said aqueous phase comprising: an emulsifying agent selected from the class of polysorbates in an amount of 0.1 to 0.2% w/v, based on the total volume of the formulation; a sugar or a sugar alcohol in an amount of 5.0 to 5.2% w/v, based on the total volume of the formulation; a mixture of microcrystalline cellulose and carboxymethylcellulose sodium in an amount of 0.5 to 1.0% w/v, based on the total volume of the formulation; one or more preservatives; and water up to 100%, is effective for the prophylaxis and/or treatment of a dermatological disease such as atopic dermatitis, acne and psoriasis.Type: GrantFiled: May 2, 2012Date of Patent: March 25, 2014Assignee: Chiesi Farmaceutici S.p.A.Inventor: Salvatore Criscione
-
Patent number: 8680032Abstract: The invention relates to microencapsulated colorant granules consisting of a core (A) and a shell (B), whereby the core (A) has a diameter of between 1 and 1000 micrometer and comprises a) a colorant (I), b) microcrystalline cellulose, c) a polyol; and whereby the shell (B) has a thickness of between 1 to 500 micrometer and comprises d) a polymer selected from the group consisting of polycarboxylic acids, vinyl polymers, styrene-(meth)acrylic copolymers, cellulose and cellulose derivatives. The invention further relates to cleansing compositions, such as hand soaps, containing said microencapsulated colorant granules.Type: GrantFiled: July 15, 2010Date of Patent: March 25, 2014Assignee: Clariant Finance (BVI) LimitedInventors: Angela Lachmann, Harald Oswald, Sambit Roy, Sharmad Chandratre
-
Publication number: 20140079789Abstract: One or more particles of bioactive glass coated with a glycosaminoglycan, wherein the glycosaminoglycan is bound to the bioactive glass and methods of treatment using such particles.Type: ApplicationFiled: September 18, 2013Publication date: March 20, 2014Applicant: NOVABONE PRODUCTS, LLCInventors: Gregory J. POMRINK, Zehra TOSUN
-
Patent number: 8663683Abstract: Pharmaceutical compositions of topiramate for once-a-day oral administration are provided. The formulations comprise a sustained-release component and an optional immediate-release component, the compositions of which can be selectively adjusted, respectively, to release the active ingredient along a pre-determined release profile. Method of treating or preventing pathological disorders in mammalian subjects comprising the administration of the novel formulations disclosed herein is also provided.Type: GrantFiled: August 27, 2012Date of Patent: March 4, 2014Assignee: Supernus Pharmaceuticals, Inc.Inventors: Likan Liang, Hua Wang, Padmanabh P. Bhatt, Michael L. Vieira
-
Patent number: 8663703Abstract: Provided are microparticles of active pharmaceutical ingredients, which are prepared by removing a sublimable carrier from a solid solution of the a active pharmaceutical ingredients in the sublimable carrier. Also provided are drug delivery vehicles comprising a carrier particle bearing the microparticles on its surface.Type: GrantFiled: December 10, 2009Date of Patent: March 4, 2014Assignee: Teva Pharmaceutical Industries, Ltd.Inventors: E. Itzhak Lerner, Vered Rosenberger, Moshe Flashner-Barak, Anna Drabkin, Naomi Moldavski
-
Publication number: 20140056957Abstract: Methods and compositions are provided for generating and applying long-lasting therapeutic nitric oxide (NO) gas from the reaction of water-soluble chemical reactants microencapsulated in polymer matrices. In some applications the microencapsulated reactants are introduced in an aqueous gel, and in other applications they are introduced to the area of therapy either directly or in a medical device such as a therapeutic pad or dressing. In some applications, the microencapsulated chemical precursors are maintained in close physical proximity to one another in a limited volume, and using a limited amount of solvent residing within that same volume to extract and process the chemical precursors to form NO.Type: ApplicationFiled: August 16, 2013Publication date: February 27, 2014Applicant: NIOXX LLCInventors: Cheng-Shing Chen, Ferid Murad, Kenneth A. Smith, WIlliam A. Seitz, William J. Merrell, Alexandru T. Balaban
-
Publication number: 20140044793Abstract: A composition comprising a core material, having a taste value and a polymeric coating. The polymeric coating substantially surrounds the core material and comprises a cationic polymer and optionally an anionic polymer. The polymeric coating has a uniform thickness ranging from 2 ?m to 20 ?m. The composition provides release of a portion of the core material which is taste masked over a time period ranging from 0.5 minute to 2 minutes in the oral cavity and provides a modified-release of the remaining core material in a gastrointestinal tract.Type: ApplicationFiled: September 20, 2011Publication date: February 13, 2014Applicant: SPI PHARMA, INC.Inventors: Diane Goll, Cecil W. Propst
-
Publication number: 20140037744Abstract: Disclosed is a microcapsule including a core having an oxidizable active (OA), the outer part of said core being in a solid form, and a water insoluble coating obtained from an encapsulating agent (EA), with the coating surrounding said core. In particular, there is disclosed a microcapsule wherein the EA is water soluble or organic solvent, in particular ethanol, soluble, or a microcapsule wherein said EA is an agent, the water solubility of which is pH-dependent. In particular, the core does not consist in or comprise a metal oxide, and the coating does not comprise a disintegrant, in particular sodium starch glycolate. Also disclosed is a process for preparing the microcapsules.Type: ApplicationFiled: October 16, 2013Publication date: February 6, 2014Applicant: IDCAPSInventors: Pierre BUISSON, Carine CHAIGNEAU, Jean-Eudes VENDEVILLE
-
Publication number: 20140037743Abstract: The presently claimed and disclosed inventive concept(s) contemplates a novel polymeric oral dosage form (transmucosal delivery vehicle) for delivery of pharmaceutical and nutriceutical bioactive agents to the mucosa and bloodstream of the intestine. The oral dosage form of the presently claimed and disclosed inventive concept(s) comprises a polymeric coating which encapsulates the bioactive agent and inhibits degradation and dissolution of the bioactive agent within the stomach and within the lumen of the intestine until after passing through the mucosal wall of the small and/or large intestine. The enzymatic degradation of the polymeric delivery vehicle containing the bioactive agent is substantially inhibited until after absorption of the polymeric delivery vehicle into blood vessels of the intestinal mucosa.Type: ApplicationFiled: October 11, 2013Publication date: February 6, 2014Applicant: DelivRx, Inc.Inventor: Daniel R. DeBrouse
-
Publication number: 20140037742Abstract: By combining the anti-bacterial effects of silver sulfadiazine and silver nanoparticles with the absorption and slow-release capabilities of alginate, a product was created that can be used to heal and protect deep wounds. These microparticles can have a greater surface area to volume ratio. This, in turn, can permit the particles to have a larger area of exposure to bacterial colonies, thereby increasing antimicrobial activity. Additionally, engineered microparticles also may benefit from the ability to conform to the shape of the wound.Type: ApplicationFiled: July 30, 2013Publication date: February 6, 2014Inventor: Melissa Fagan
-
Publication number: 20140030349Abstract: A formulation which comprises coated granules and a water-soluble gel, wherein the coated granules comprise an oil absorbent which comprises cashew nut shell liquid, anacardic acid, cardanol, or cardol, and wherein the coated granules are suspended in the water-soluble gel.Type: ApplicationFiled: April 18, 2012Publication date: January 30, 2014Applicant: Idemitsu Kosan Co., Ltd.Inventors: Shinji Ito, Seika Ooiwa
-
Publication number: 20140030348Abstract: The invention relates to dosage forms that provide prolonged therapy. In particular, the invention relates to dosage forms including various pluralities of drug-containing resin particles. The invention also relates to methods of making these dosage forms and methods of treating using these dosage forms.Type: ApplicationFiled: March 15, 2013Publication date: January 30, 2014Applicant: NEOS THERAPEUTICS, LPInventors: Mark Tengler, Russell McMahen
-
Publication number: 20140017308Abstract: Compositions comprising a fatty acid oil mixture, at least one free fatty acid, and at least one statin or pharmaceutically acceptable salt, hydrate, solvate, or complex thereof, and uses thereof are disclosed. Further disclosed are preconcentrates capable of forming a self-nanoemulsifying drug delivery system (SNEDDS), a self-microemulsifying drug delivery system (SMEDDS), or self-emulsifying drug delivery systems (SEDDS) in an aqueous solution.Type: ApplicationFiled: September 8, 2011Publication date: January 16, 2014Applicant: Pronova Biopharma Norge ASInventors: Svein Olaf Hustvedt, Gunnar Berge, Preben Houlberg Olesen, Anette Müllertz
-
Publication number: 20140017326Abstract: Polysaccharide derivatives having a median Equivalent Projected Circle Diameter (EQPC) of less than 140 micrometers and a particle size and shape distribution meeting condition A or B or both are useful for preparing dosage forms, particularly for preparing compressed sustained-release dosage forms: A. non-compacted polysaccharide derivative particles have a flowability of at least 45 g/sec through a vertically inverted cone having a vertex angle of about 40 and an outlet diameter of about 50 mm, or B. i) no more than 40 volume percent of the polysaccharide derivative particles are fine particles having a particle length LEFI of less than 40 micrometers and ii) no more than 40 volume percent of the polysaccharide derivative particles are fibrous particles, and the sum of the fine particles and the fibrous particles does not exceed 50 volume percent.Type: ApplicationFiled: March 29, 2012Publication date: January 16, 2014Applicant: DOW GLOBAL TECHNOLOGIES LLCInventors: Jennifer L'hote-Gaston, Nicholas S. Grasman, Jorg Theuerkauf, Sjoerd A. De Vries
-
Patent number: 8617610Abstract: Disclosed are compositions including powdered green tea extract and a powdered preparation comprising polyunsaturated fatty acids. Also disclosed are methods of preparing the compositions and using the compositions in food products, as well as food products containing or that are prepared from the compositions.Type: GrantFiled: May 21, 2012Date of Patent: December 31, 2013Assignee: DSM Nutritional Products AGInventors: Amber Lynn Gareau, Sharon Ann Spurvey Pittman, Lariza Beristain Taboada
-
Publication number: 20130343996Abstract: The present invention relates to graphite-coated magnetic nanoparticles, methods for the synthesis of graphite-coated magnetic nanoparticles, and methods of using graphite-coated magnetic nanoparticles for targeted delivery of siRNA-based therapy, as multimodal imaging probes and for hyperthermia cancer treatment.Type: ApplicationFiled: April 25, 2013Publication date: December 26, 2013Applicant: Rutgers, The State University of New JerseyInventor: Rutgers, The State University of New Jersey
-
Patent number: 8613955Abstract: Methods of producing microparticles, and especially chitin microparticles (CMP), are disclosed that involve reducing the size of (larger) particles using a (high shear) microfluidising instrument.Type: GrantFiled: April 30, 2009Date of Patent: December 24, 2013Assignee: Mucovax Inc.Inventor: Peter Strong
-
Publication number: 20130336891Abstract: Formulation of acoustically activatable particles having low vaporization energy and methods for using same are disclosed. According to one aspect, a method of producing particles of materials includes, with a first substance that includes at least one component that is a gas at room temperature and atmospheric pressure, performing one of: causing the first substance to condense to a liquid phase, and extruding or emulsifying the first substance into or in the presence of a second substance to create a droplet or emulsion in which the first substance is encapsulated by the second substance; or extruding or emulsifying the first substance into or in the presence of a second substance to create a bubble in which the first substance is encapsulated by the second substance and wherein at least some of the first substance is in a gaseous phase, and causing the first substance to condense to a liquid phase, which causes the bubble to transform into a droplet or emulsion.Type: ApplicationFiled: October 11, 2011Publication date: December 19, 2013Applicant: THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILLInventors: Paul A. Dayton, Paul S. Sheeran, Terry O. Matsunaga, Mark A. Borden
-
Publication number: 20130337070Abstract: Disclosed herein are compositions useful as therapy and prevention of skin neoplasms, namely melanoma. Also disclosed herein are methods of using polymer-coated cerium nanoparticles as therapy against skin cancer. Further, disclosed are combination therapies involving polymer-coated cerium nanoparticles with other anti-neoplastic agents.Type: ApplicationFiled: May 28, 2013Publication date: December 19, 2013Applicant: University of Central Florida Research Foundation Inc.Inventors: Peter Brenneisen, Sudipta Seal
-
Patent number: 8609835Abstract: The present invention relates to purification and use of a novel emulsion stabilizing polysaccharide. In particular, a polyelectrolyte exopolysaccharide with high molecular weight comprising a high molecular weight polymer with a tri-saccharide repeating unit is disclosed. In one aspect of the invention, methods are directed to isolating and purifying a high molecular weight exopolysaccharide (EPS) from a cell supernatant. In another aspect, methods are disclosed for isolating a lipopolysaccharide (LPS) and a high molecular weight Acinetobacter polyelectrolyte exopolysaccharide (APE) from Acinetobacter bacteria. Compositions are also directed to lipid nanoparticles comprising a therapeutic agent encapsulated by a high molecular weight polysaccharide and nanoparticles comprising a therapeutic agent bound to a cationic polysaccharide cross-linked with a polyanion.Type: GrantFiled: May 28, 2009Date of Patent: December 17, 2013Assignee: Trustees Of Tufts CollegeInventors: David L. Kaplan, Bruce Panilaitis, Michael Mercaldi, Hanna Dams-Kozlowska
-
Publication number: 20130330411Abstract: An oral cyclosporin composition comprises minicapsules having a core containing a cyclosporin, especially cyclosporin A in a solubilised liquid form. The minicapsules have a release profile to release the pre-solubilised cyclosporin, at least in the colon. The composition may be used for treating a range of intestinal diseases [FIG. 10].Type: ApplicationFiled: July 15, 2013Publication date: December 12, 2013Inventor: Ivan Coulter
-
Publication number: 20130330279Abstract: The present disclosure provides compositions and methods of treating Breast Cancer. Disclosed is a nanoparticle paired to at least one of W genetic materials that suppress key regulators of fat synthesis (e.g. Rev-erb) to cause a predefined target cell types apoptosis or X predefined targeting moieties that cause predefined target cell types apoptosis and correspond to Y predefined target parameters associated with Z predefined target cell types in connection with treatment of at least one of the following breast cancer, glioblastoma, head and neck cancer, pancreatic cancer, lung cancer, cancer of the nervous system, gastrointestinal cancer, prostate cancer, ovarian cancer, kidney cancer, retina, cancer, skin cancer, liver cancer, genital.Type: ApplicationFiled: December 22, 2012Publication date: December 12, 2013Applicant: NNANOAXIS, LLCInventors: Krishnan Chakravarthy, Robert Spengler, Tracey Ignatowski, Siddhartha Kamisetti
-
Patent number: 8603537Abstract: Prasugrel containing quickly released stable oral pharmaceutical compositions containing micronized prasugrel base, and starch or a starch derivative, and processes for the preparation thereof, and the use thereof for treating atherothrombotic events of patients suffering from acute coronary syndrome in which patients were subjected to percutaneous coronary intervention.Type: GrantFiled: April 2, 2012Date of Patent: December 10, 2013Assignee: Egis Pharmaceuticals PLCInventors: András Fehér, Zsolt Zsigmong, Péter Tonka-Nagy, György Tibor Ujfalussy
-
Patent number: 8597932Abstract: The invention involves developing and stabilizing cultivating droplets within a matrix of a porous medium. A cultivation medium may be selected, prepared and mixed with a surfactant. Where cells are desired to be cultured in droplets, cells may be added. The mixture may be converted into cultivating droplets. The cultivating droplets may be stabilized by introducing them to a porous medium. The porous medium may contain hydrophobic particles. Stabilized, cultivating droplets having one or more cells may form an aseptic microenvironment for the concentrated growth of cells.Type: GrantFiled: May 22, 2006Date of Patent: December 3, 2013Assignee: George Mason Intellectual Properties, Inc.Inventors: Victor Morozov, Charles L. Bailey, Nikolai N. Vsevolodov
-
Publication number: 20130316007Abstract: The present invention relates to a microcapsule preparation product of alginate-chitosan acyl derivatives, which is produced by mixing microcapsules of alginate-chitosan acyl derivatives with an aqueous solution, wherein the biomicrocapsule structureconsists of two parts, a microcapsule membrane and an inner core; the microcapsule membrane is a polyelectrolyte composite hydrogel membrane formed by chitosan, alginates and chitosan acyl derivatives, and the inner core is an alginate liquid or a hydrogel environment containing cells.Type: ApplicationFiled: November 28, 2011Publication date: November 28, 2013Applicant: Dalian Institute of Chemical Physics, Chinese Academy of SciencesInventors: Xiaojun Ma, Weiting Yu, Hongguo Xie, Xiudong Liu, Weiyang Xie, Guoshuang Zheng
-
Patent number: 8591928Abstract: A pesticide granule is provided that includes a base carrier particle. A liquid pesticide coating is applied to the particle surface. The coating may contain adjuvants. The coating has sufficient tack to adhere a second powdered pesticide to the carrier particle. The usage of tackifying agents to render the particle surface tacky enough to adhere powdered pesticide is reduced or eliminated. The powdered pesticide is sized to a mean diameter of less than 10% of the carrier diameter to promote adhesion. The synergistic rapid acting pesticide delivery associated with the granule results in the usage of less pesticide to control a given pest with reduced environmental impact. Bifenthrin is a representative of the liquid pesticide.Type: GrantFiled: January 3, 2011Date of Patent: November 26, 2013Assignee: The Andersons, Inc.Inventors: Timothy D. Birthisel, James R. Lynch, Matthew G. Johnston
-
Publication number: 20130309313Abstract: Disclosed are compositions including powdered green tea extract and a powdered preparation comprising polyunsaturated fatty acids. Also disclosed are methods of preparing the compositions and using the compositions in food products, as well as food products containing or that are prepared from the compositions.Type: ApplicationFiled: May 21, 2012Publication date: November 21, 2013Applicant: OCEAN NUTRITION CANADA LIMITEDInventors: Amber Lynn Gareau, Sharon Ann Spurvey Pittman, Lariza Beristain Taboada
-
Patent number: 8586094Abstract: Disclosed is a pharmaceutically acceptable oral dosage form comprising fenofibrate, phospholipid, a buffer salt, a water-soluble bulking agent selected from maltodextrin, mannitol, and combinations thereof, a cellulosic additive, beads or crystals of a pharmaceutically acceptable water-soluble excipient support material, a polyvinylpyrrolidone or crospovidone, croscarmellose sodium, granular mannitol, sodium dodecyl sulfate, silicon dioxide, and a stearate, wherein the fenofibrate is in the form of microparticles, and wherein at least a portion of the phospholipid is coated on the surfaces of the fenofibrate microparticles, the phospholipid coated microparticles are embedded in a matrix comprising the water-soluble bulking agent, phospholipid that is not coated on the microparticles, the buffer salt and the cellulosic additive, and the matrix is coated on up to 100% of the surfaces of the beads or crystals of the excipient support material.Type: GrantFiled: May 2, 2003Date of Patent: November 19, 2013Assignee: Jagotec AGInventors: Michael Vachon, Mishra K. Awadesh, Robert A. Snow, Pol-Henri Guivarc'H
-
Publication number: 20130295187Abstract: A method for treating a subject, such as a human patient, having a vascular disorder. The treatment method administers a therapeutic effective amount of a nanoparticle or a chemical structure to the subject to treat the disorders. The nanoparticle includes a poly L-arginine polymer and a Factor VIIa inhibitor conjugated to, or encapsulated in, the poly L-arginine polymer. The chemical structure includes a Factor VIIa inhibitor that includes at least one nitric oxide (NO) donor. The disorder may be sickle cell disease; stimulated or pathological angiogenesis associated disorders, cancer, ocular angiogenesis-mediated disorders such as diabetic retinopathy and macular degeneration, coagulation and/or platelet activation-associated disorders, pulmonary hypertension, or combinations thereof.Type: ApplicationFiled: July 5, 2013Publication date: November 7, 2013Inventor: Shaker A. Mousa
-
Patent number: 8575332Abstract: The present invention provides long-acting sustained-release formulations of drugs such as proteins or peptides, which are injectable, completely biodegradable and safe, as well as ensuring efficient encapsulation of the drugs such as proteins or peptides without inhibiting their biological activity. It is possible to achieve injectable sustained-release formulations that ensure efficient encapsulation and long-term sustained release of drugs such as proteins or peptides while retaining their biological activity, when a solution containing a drug and a polysaccharide derivative such as hyaluronic acid having a crosslinkable functional group(s) or a salt thereof is dehydrated in microparticulate form starting from a dilute state, where crosslinking proceeds slowly, to reach a concentration which facilitates crosslinking, to thereby cause crosslinking reaction during concentration, so that the drug is encapsulated into the crosslinked polysaccharide to give drug-carrying microparticles.Type: GrantFiled: November 15, 2004Date of Patent: November 5, 2013Assignee: Chugai Seiyaku Kabushiki KaishaInventors: Sei Kwang Hahn, Tsuyoshi Shimoboji
-
Patent number: RE44812Abstract: Process for extracting hydrophobin from a solution wherein carrageenan is added to the solution and the pH of the solution is brought below 3.5, and the ionic strength of the solution is below 0.5.Type: GrantFiled: July 30, 2013Date of Patent: March 18, 2014Assignee: Conopco, Inc.Inventor: Nicholas David Hedges